Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126074161 | 12607416 | 1 | I | 20160725 | 20160729 | 20160729 | EXP | BR-PFIZER INC-2016362465 | PFIZER | 82.00 | YR | M | Y | 71.00000 | KG | 20160729 | CN | BR | BR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126074161 | 12607416 | 1 | PS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 75 MG, 1X/DAY | 20699 | 75 | MG | PROLONGED-RELEASE CAPSULE | QD | ||||||
126074161 | 12607416 | 2 | SS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | 20699 | PROLONGED-RELEASE CAPSULE | |||||||||||
126074161 | 12607416 | 3 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 10 MG, 1 TABLET PER DAY | 0 | 10 | MG | TABLET | |||||||
126074161 | 12607416 | 4 | C | LOSARTAN. | LOSARTAN | 1 | Oral | UNK | 0 | ||||||||||
126074161 | 12607416 | 5 | C | ATENOLOL. | ATENOLOL | 1 | Oral | UNK | 0 | ||||||||||
126074161 | 12607416 | 6 | C | CLOPIDOGREL BISULFATE. | CLOPIDOGREL BISULFATE | 1 | Oral | 1 DF, 1 TABLET PER DAY | 0 | 1 | DF | TABLET | |||||||
126074161 | 12607416 | 7 | C | SOMALGIN CARDIO | ASPIRINDIHYDROXYALUMINUM AMINOACETATE ANHYDROUSMAGNESIUM CARBONATE | 1 | Oral | UNK, 1X/DAY | 0 | QD | |||||||||
126074161 | 12607416 | 8 | C | SYNTHROID | LEVOTHYROXINE SODIUM | 1 | Oral | 1 DF, 1 TABLET PER DAY AT FASTENING | 0 | 1 | DF | TABLET | |||||||
126074161 | 12607416 | 9 | C | SYNTHROID | LEVOTHYROXINE SODIUM | 1 | 0 | TABLET | |||||||||||
126074161 | 12607416 | 10 | C | ANGIPRESS | ATENOLOL | 1 | Oral | 50 MG, 1 TABLET DAILY AT FASTENING | 0 | 50 | MG | TABLET | |||||||
126074161 | 12607416 | 11 | C | LANZOPRAZOL | LANSOPRAZOLE | 1 | Oral | 40 MG, 1 TABLET AT FASTENING | 0 | 40 | MG | TABLET |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126074161 | 12607416 | 1 | Depression |
126074161 | 12607416 | 2 | Stress |
126074161 | 12607416 | 3 | Blood cholesterol |
126074161 | 12607416 | 4 | Blood pressure increased |
126074161 | 12607416 | 5 | Blood pressure increased |
126074161 | 12607416 | 6 | Anticoagulant therapy |
126074161 | 12607416 | 7 | Anticoagulant therapy |
126074161 | 12607416 | 8 | Hormone replacement therapy |
126074161 | 12607416 | 9 | Thyroid disorder |
126074161 | 12607416 | 10 | Cardiac disorder |
126074161 | 12607416 | 11 | Abdominal discomfort |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126074161 | 12607416 | OT |
126074161 | 12607416 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126074161 | 12607416 | Activities of daily living impaired | |
126074161 | 12607416 | Blindness | |
126074161 | 12607416 | Decreased appetite | |
126074161 | 12607416 | Depression | |
126074161 | 12607416 | Dizziness | |
126074161 | 12607416 | Drug ineffective | |
126074161 | 12607416 | Eye disorder | |
126074161 | 12607416 | Hallucination, visual | |
126074161 | 12607416 | Malaise |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126074161 | 12607416 | 1 | 201506 | 0 | ||
126074161 | 12607416 | 3 | 201506 | 0 | ||
126074161 | 12607416 | 4 | 201506 | 0 | ||
126074161 | 12607416 | 5 | 201506 | 0 | ||
126074161 | 12607416 | 6 | 201506 | 0 | ||
126074161 | 12607416 | 7 | 201506 | 0 | ||
126074161 | 12607416 | 8 | 201306 | 0 | ||
126074161 | 12607416 | 10 | 2011 | 0 |